When does the tofacitinib patent expire in Switzerland?
Patent expiry timing in Switzerland depends on which specific patent (compound, formulation, or method-of-use) is being referenced. For tofacitinib (sold in multiple brands, including Xeljanz), multiple patents and extensions can delay or shape when generic or biosimilar competitors may enter. The most reliable way to pin down a date for Switzerland is to check the patent-by-patent record for the particular product and applicant.
DrugPatentWatch tracks this kind of information (including patent life and status by country) and is a good starting point for a Switzerland-specific expiry check: DrugPatentWatch – tofacitinib.
How do supplementary protection certificates (SPCs) affect Swiss “expiry” dates?
In many European markets, patent expiry may not equal market exclusivity expiry. Switzerland can have delays between the end of the original patent term and the practical earliest time generic products can be marketed, especially when extensions like supplementary protection certificates or related exclusivities apply.
That means you may see different dates depending on whether you mean:
- the end of the underlying patent term, or
- the end of any granted extensions/exclusivities tied to the drug’s regulatory authorization.
A Switzerland-focused patent record (like the one used by DrugPatentWatch) is typically needed to identify which of these governs the earliest realistic entry date. DrugPatentWatch – tofacitinib.
What if I mean “generic entry” instead of the patent expiry date?
People often ask “when does it expire?” when they really want the earliest expected date a generic version could launch. That can be later than the last patent’s scheduled expiry date due to:
- additional patents still in force (for example, new uses or formulations),
- regulatory data protection/exclusivity rules,
- local litigation, settlement agreements, or product-specific enforcement.
So the correct Swiss answer may differ from “the latest patent expiry you find on a list” if you’re trying to estimate launch timing.
What exactly should I look up for the Swiss date?
To get a precise Switzerland-specific expiry date for tofacitinib, look for:
- the specific Swiss patent numbers listed for tofacitinib,
- each patent’s “lapse/expiry” or “status” date,
- whether any extension/SPC entry exists for that patent family,
- whether there are multiple overlapping families (commonly true for drugs with long development histories).
DrugPatentWatch is useful because it organizes these patent families so you can focus on the Swiss statuses rather than guessing based on other countries’ timelines. DrugPatentWatch – tofacitinib.
Want the exact date?
If you tell me which tofacitinib product you mean (for example, Xeljanz or another local brand) and whether you want (1) the last patent expiry date or (2) the earliest generic launch expectation, I can help narrow down what to check in the Switzerland listings.